Ovid Therapeutics (OVID) Non-Current Debt (2019 - 2020)
Ovid Therapeutics (OVID) posted Non-Current Debt of $61200.0 for Q4 2020, little changed on a QoQ basis from $61200.0 in Q3 2020, and down 78.64% year-over-year from $286562.0 in Q1 2020.
Ovid Therapeutics (OVID) Non-Current Debt (2019 - 2020) Analysis & Trends
Ovid Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $61200.0 for Q4 2020.
- Quarterly Non-Current Debt fell 78.64% year-over-year to $61200.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $61200.0 (down 78.64% YoY) and the FY2020 annual result came in at $61200.0, down 78.64% from the prior year.
- Non-Current Debt was $61200.0 for Q4 2020 at Ovid Therapeutics, roughly flat from $61200.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.3 million in Q1 2019 and bottomed at $61200.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 61,200.00 |
| Sep 30, 2020 | 61,200.00 |
| Jun 30, 2020 | 286,562.00 |
| Mar 31, 2020 | 286,562.00 |
| Dec 31, 2019 | 286,562.00 |
| Sep 30, 2019 | 286,562.00 |
| Jun 30, 2019 | 286,562.00 |
| Mar 31, 2019 | 1.34 Mn |